Status:
TERMINATED
Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease
Lead Sponsor:
AN2 Therapeutics, Inc
Conditions:
MAC Lung Disease
Treatment Refractory MAC Lung Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
This is a pivotal Phase 2/3, double-blind, placebo-controlled study of epetraborole + OBR (Optimized Background Regimen) versus placebo + OBR in patients with treatment-refractory MAC lung disease. Th...
Detailed Description
In the Phase 2 part of the study, approximately 80 patients will be randomized in a 1:1 ratio (40 patients receiving active epetraborole tablets and 40 patients receiving matching placebo tablets). Th...
Eligibility Criteria
Inclusion
- Male or female patients who are 18 years of age or older.
- Willing and able to provide written informed consent.
- Patients with a diagnosis of treatment-refractory MAC lung disease consisting of all of the following (a) Microbiological, (b) Clinical, and (c) Radiographic criteria:
- Microbiological criteria:
- One Pre-Study MAC-positive respiratory specimen. Documentation of a MAC positive specimen collected per standard of care within 6 months prior to signing the informed consent form (ICF).
- One Screening MAC-positive expectorated or induced sputum sample.
- Clinical criteria: At least 2 of the following patient-reported clinical symptoms:
- Cough with sputum production
- Cough without sputum
- Chest congestion
- Hemoptysis
- Dyspnea
- Fatigue
- Night sweats or unusual sweating
- Radiographic criteria: Non contrast Chest CT scan within 6 months prior to signing the ICF with abnormalities consistent with MAC lung disease.
- OBR criteria: An OBR is a combination regimen that consists of ≥2 antimycobacterial agents. The patient-specific OBR must be administered for a minimum duration of 6 consecutive months that is either ongoing at the time of Screening or was stopped or paused no more than 12 months before screening. The OBR regimen administered during Screening must be continued after randomization.
- Patients who are willing to comply with all the study activities and procedures throughout the duration of the study and comply with all planned study visits and study procedures from Screening through the LFU Visit.
- All patients must agree to use an effective method of birth control.
- Patients expected to survive with continued antimycobacterial therapy and appropriate supportive care from Screening through the LFU Visit, in the judgment of the Investigator.
Exclusion
- Patients with a presence of any suspected or confirmed disease or condition at Screening or the time of randomization that, in the opinion of the Investigator, may confound the assessment of symptom-based clinical response.
- Patients with active pulmonary malignancy or any malignancy that required or would require chemotherapy or radiation therapy within 1 year prior to randomization through the LFU Visit.
- Patients with creatinine clearance (CrCl) of ≤30 mL/min, as estimated by the Cockcroft Gault formula, at Screening.
- Patients with hemoglobin \<10.0 g/dL or \<6.2 mmol/L at Screening; donation of blood or plasma within 28 days prior to randomization; or symptomatic loss of blood or hemorrhage within 28 days prior to randomization.
- Patients with severe hemoptysis within 28 days prior to randomization, defined as \>100 mL over any 24-hour period or severe or extremely severe hemoptysis.
- Patients with severe hepatic impairment, as evidenced by alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>3 × upper limit of normal (ULN) or total bilirubin \>2 × ULN, or clinical signs of cirrhosis or end-stage hepatic disease.
- Patients who are pregnant or breastfeeding.
- Patients with a mean QT interval corrected using Fridericia's formula (QTcF) \>480 msec based on triplicate 12-lead ECGs at Screening.
- Patients with an immunodeficiency or an immunocompromised condition and risk for an opportunistic pulmonary infection.
- Patients with an anticipated start of new non-study antimycobacterial therapy to be administered at any time between Screening and Month 6.
- Patients who have received any investigational medication during the 30 days or 5 half-lives, whichever is longer, prior to randomization.
- Patients with any prior exposure to epetraborole.
- Patients with any condition that, in the opinion of the Investigator, interferes with the ability to safely complete the study or adhere to study requirements, including the patient's inability or unwillingness to comply with all study assessments and visits.
Key Trial Info
Start Date :
May 20 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 18 2024
Estimated Enrollment :
177 Patients enrolled
Trial Details
Trial ID
NCT05327803
Start Date
May 20 2022
End Date
December 18 2024
Last Update
May 8 2025
Active Locations (91)
Enter a location and click search to find clinical trials sorted by distance.
1
423032
Birmingham, Alabama, United States, 35233
2
423037
Tucson, Arizona, United States, 85724
3
423070
Sacramento, California, United States, 95817
4
423069
San Francisco, California, United States, 94143